Skip to main content
    P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.19
    -0.08 (-1.87%)

    Market Cap: $949.85M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Prime Medicine, Inc. Common Stock (PRME) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Prime Medicine, Inc. Common Stock (PRME) to earn -$0.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $9.31M. Of 14 analysts, 11 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.14, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.

    RatingAnalystsShare
    Strong Buy17.1%
    Buy1071.4%
    Hold321.4%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 26.7%.

    Fiscal year ending Dec 31, 2026
    -$0.96
    EPS consensus, revenue $9.31M
    Fiscal year ending Dec 31, 2027
    -$0.88
    EPS consensus, revenue $11.80M
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.96-$0.96 to -$0.953$9.31M$2.01M to $53.01M12
    Dec 31, 2027-$0.88-$1.22 to -$0.6712$11.80MN/A11

    Quarterly Estimates

    The EPS consensus falls from -$0.23 for the quarter ending Dec 31, 2026 to -$0.26 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.23-$0.31 to -$0.0417$2.40MN/A14
    Mar 31, 2027-$0.26-$0.35 to -$0.196$1.09MN/A5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 11 upward and 8 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202673
    Fiscal year ending Dec 31, 202735
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.95.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.96-$0.95-$0.94-$0.93-$0.95N/A
    Fiscal year ending Dec 31, 2027-$0.88-$0.90-$0.89-$0.88-$0.86N/A
    Quarter ending Mar 31, 2027-$0.26-$0.26-$0.26-$0.26-$0.30N/A

    Frequently Asked Questions About PRME

    What is the PRME stock forecast?

    Consensus analyst estimates put Prime Medicine, Inc. Common Stock's EPS at -$0.96 for the fiscal year ending Dec 31, 2026, on revenue of $9.31M. The consensus rating from 14 analysts is Buy.

    How do analysts rate PRME stock?

    Of 14 analysts covering Prime Medicine, Inc. Common Stock, 1 rates it Strong Buy, 10 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PRME next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.96, with estimates from -$0.96 to -$0.95 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.88, with estimates from -$1.22 to -$0.67 from 12 analysts.

    What revenue do analysts expect from Prime Medicine, Inc. Common Stock next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $9.31M, with estimates from $2.01M to $53.01M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $11.80M.

    How many analysts cover PRME?

    14 analysts rate Prime Medicine, Inc. Common Stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.